Priftin

Priftin has been approved for the treatment of pulmonary tuberculosis. Priftin must always be used in conjunction with at least one other antituberculosis drug to which Mycobacterium tuberculosis is susceptible. Priftin should be administered twice weekly for two months, with an interval of no less than three days (72 hours) between doses, as part of an appropriate regimen which includes companion drugs.

The most common adverse events related to treatment with Priftin combination therapy include hyperuricemia, increased liver function tests, neutropenia, pyuria, proteinuria, and lymphopenia.